Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core

Journal Article · · Journal of Medicinal Chemistry

WD repeat domain 5 (WDR5) is a member of the WD40-repeat protein family that plays a critical role in multiple chromatin-centric processes. Overexpression of WDR5 correlates with a poor clinical outcome in many human cancers, and WDR5 itself has emerged as an attractive target for therapy. Most drug-discovery efforts center on the WIN site of WDR5 that is responsible for the recruitment of WDR5 to chromatin. In this paper, we describe discovery of a novel WDR5 WIN site antagonists containing a dihydroisoquinolinone bicyclic core using a structure-based design. These compounds exhibit picomolar binding affinity and selective concentration-dependent antiproliferative activities in sensitive MLL-fusion cell lines. Furthermore, these WDR5 WIN site binders inhibit proliferation in MYC-driven cancer cells and reduce MYC recruitment to chromatin at MYC/WDR5 co-bound genes. Thus, these molecules are useful probes to study the implication of WDR5 inhibition in cancers and serve as a potential starting point toward the discovery of anti-WDR5 therapeutics.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
National Institutes of Health (NIH); National Cancer Institute (NCI); USDOE Office of Science (SC); Michigan Economic Development Corporation and Michigan Technology Tri-Corridor
Grant/Contract Number:
AC02-06CH11357
OSTI ID:
1598029
Journal Information:
Journal of Medicinal Chemistry, Journal Name: Journal of Medicinal Chemistry Journal Issue: 2 Vol. 63; ISSN 0022-2623
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (46)

Up‐regulated WDR5 promotes gastric cancer formation by induced cyclin D1 expression journal December 2017
Structure and function of WD40 domain proteins journal March 2011
Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization journal September 2004
MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia journal June 2017
In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer journal June 2016
Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity journal March 2019
A Twist1-MLL-WDR5-HOTTIP Complex Regulates HOXA9 Chromatin to Facilitate Metastasis of Prostate Cancer journal September 2014
Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia journal January 2014
Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC journal May 2015
MLL: a histone methyltransferase disrupted in leukemia journal October 2004
The Myc oncoprotein as a therapeutic target for human cancer journal August 2006
WD40 proteins propel cellular networks journal October 2010
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997
The WD repeat: a common architecture for diverse functions journal May 1999
Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1) journal March 2016
Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction journal June 2017
Discovery of Potent 2-Aryl-6,7-dihydro-5 H -pyrrolo[1,2- a ]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design journal June 2018
Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT) journal April 2015
Analysis of the Binding of Mixed Lineage Leukemia 1 (MLL1) and Histone 3 Peptides to WD Repeat Domain 5 (WDR5) for the Design of Inhibitors of the MLL1−WDR5 Interaction journal July 2010
PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis by directly targeting ZNF407 journal March 2017
The MLL recombinome of acute leukemias in 2013 journal April 2013
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth journal September 2015
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia journal July 2015
MLL translocations, histone modifications and leukaemia stem-cell development journal November 2007
MYC as a regulator of ribosome biogenesis and protein synthesis journal April 2010
Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation journal February 2015
Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer journal March 2011
Structure of WDR5 Bound to Mixed Lineage Leukemia Protein-1 Peptide journal October 2008
Structural Basis for WDR5 Interaction (Win) Motif Recognition in Human SET1 Family Histone Methyltransferases journal June 2012
Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes journal August 2016
A Conserved Arginine-containing Motif Crucial for the Assembly and Enzymatic Activity of the Mixed Lineage Leukemia Protein-1 Core Complex journal October 2008
Development and Use of Assay Conditions Suited to Screening for and Profiling of SET-Domain-Targeted Inhibitors of the MLL/SET1 Family of Lysine Methyltransferases journal May 2015
PHENIX : building new software for automated crystallographic structure determination journal October 2002
Coot model-building tools for molecular graphics journal November 2004
Overview of the CCP 4 suite and current developments journal March 2011
High-throughput screening in colorectal cancer tissue-originated spheroids journal November 2018
Overexpression of WD repeat domain 5 associates with aggressive clinicopathological features and unfavorable prognosis in head neck squamous cell carcinoma journal April 2018
The Pathogenesis of Mixed-Lineage Leukemia journal February 2012
WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma journal October 2015
TWIST1-WDR5- Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis journal May 2017
Targeting WDR5: A WINning Anti-Cancer Strategy? journal January 2019
WDR5 Expression Is Prognostic of Breast Cancer Outcome journal September 2015
WDR5 high expression and its effect on tumorigenesis in leukemia journal May 2016
The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer journal November 2018
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches journal February 2017
Moonlighting with WDR5: A Cellular Multitasker journal January 2018

Similar Records

Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models
Journal Article · Mon Dec 26 23:00:00 EST 2022 · Proceedings of the National Academy of Sciences of the United States of America · OSTI ID:2470237

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Journal Article · Wed Sep 29 00:00:00 EDT 2021 · Science Translational Medicine · OSTI ID:1837161